Cytogenetic Abnormalities Do Not Affect Prognosis in Pediatric CML
Chromosomal abnormalities such as a variant t(9;22) translocation do not appear to have significant prognostic impact on children with chronic myeloid leukemia.
Insurance Status Influences Chronic Myeloid Leukemia Survival Outcomes
Insurance status at the time of chronic myeloid leukemia diagnosis appears to have an influence on survival outcomes, with the uninsured and those on Medicaid having worse overall survival.
Challenges in Molecular Monitoring for CML Treatment Response
This video examines the challenge in optimizing and standardizing molecular monitoring for patients with chronic myeloid leukemia.
Ponatinib Extends Survival Over Transplant in Chronic Phase CML
Treatment with ponatinib yielded better overall survival compared with allogeneic stem cell transplantation in patients with chronic phase chronic myeloid leukemia with a T315I mutation.
TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension.
Final Results of Landmark Imatinib Study in CML Show Long-Term Benefit
The final, long-term analysis of the landmark IRIS study showed that imatinib’s efficacy persists over time in patients with CML, and no unacceptable late toxic or cumulative effects were observed.
Second-Generation TKIs Can Be Stopped in Many CML Patients
Cessation of second-generation TKIs yielded good treatment-free remission rates in patients with chronic myeloid leukemia who had sustained deep molecular responses.
By clicking Accept, you agree to become a member of the UBM Medica Community.